retatrutide dosing phase 2 trial in adults with obesity over 104 weeks in the highest dose group had 30.3% weight loss. Nearly 2/3 reached BMI < 30 1 in 3 reached BMI < 25 Retatrutide FDA Approval Status 2026:

How Ulta Lab Tests helps: Ulta Lab Tests provides direct online access to many individual biomarkers and GLP-1 monitoring panels, with specimen collection through established laboratory networks and secure online results

In recent years, peptide-based weight-loss drugs, such as GLP-1R agonists and GLP-1R/GIPR dual receptor agonists, have gained widespread global use

Claims about GLP-1 support rely on marketing language, placebo effects, or unproven ingredients rather than rigorous human trials

Rising costs lead insurers to drop weight loss drug coverage, further increasing patient burden, American Journal of Managed Care (2024) FDA approves first generic of once-daily GLP-1 injection to lower blood sugar in patients with type 2 diabetes, Food & Drug Administration (2024) What is medical necessity